Pharmacokinetic profiles determined for rifabutin, desacetyl rifabutin, rifampin, and desacetyl rifampin: Cmin Pre-dose and 2 hrs post dose in Period 2 on Days 27-30, 35 & 41. [clinicaltrials_resource:f5f1caa72994b5bb752ba6446c8170c6]
16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Pharmacokinetic profiles determined for rifabutin, desacetyl rifabutin, rifampin, and desacetyl rifampin: Cmin Pre-dose and 2 hrs post dose in Period 2 on Days 27-30, 35 & 41. [clinicaltrials_resource:f5f1caa72994b5bb752ba6446c8170c6]
16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
Bio2RDF identifier
f5f1caa72994b5bb752ba6446c8170c6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f5f1caa72994b5bb752ba6446c8170c6
measure [clinicaltrials_vocabulary:measure]
Pharmacokinetic profiles deter ...... , and desacetyl rifampin: Cmin
time frame [clinicaltrials_vocabulary:time-frame]
Pre-dose and 2 hrs post dose in Period 2 on Days 27-30, 35 & 41.
description
16 subjects: TMC207 400mg oral ...... orally, every day on day 20-41
identifier
clinicaltrials_resource:f5f1caa72994b5bb752ba6446c8170c6
title
Pharmacokinetic profiles deter ...... riod 2 on Days 27-30, 35 & 41.
@en
type
label
Pharmacokinetic profiles deter ...... 1caa72994b5bb752ba6446c8170c6]
@en